Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
PACB Analyst Ratings
Moderate Buy
5 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PACB Stock 12 Month Forecast
Average Price Target
$2.15
▲(58.09% Upside)
| Highest Price Target$3.00 | Average Price Target$2.15 | Lowest Price Target$1.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Scotiabank
Reiterated
04/10/25
TD Cowen
Reiterated
04/09/25
Canaccord Genuity
Reiterated
04/09/25
Barclays
Reiterated
04/09/25
Cantor Fitzgerald
Reiterated
03/18/25
Bernstein
Reiterated
03/04/25
Piper Sandler
Reiterated
02/20/25
Goldman Sachs
Reiterated
02/18/25
Morgan Stanley
Reiterated
02/18/25
Stephens
$3.5→$2.5
Buy
83.82%
Upside
Reiterated
08/13/24
PacBio price target lowered to $2.50 from $3.50 at StephensPacBio price target lowered to $2.50 from $3.50 at Stephens
Jefferies
$4
Buy
194.12%
Upside
Initiated
06/03/24
PacBio assumed with a Buy at JefferiesPacBio assumed with a Buy at Jefferies
J.P. Morgan
―
Hold
―
Downgraded
04/21/24
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (NASDAQ: CYTH), CytomX Therapeutics (NASDAQ: CTMX) and Pacific Biosciences (NASDAQ: PACB)
Nephron
$2
Hold
47.06%
Upside
Downgraded
04/16/24
Nephron downgrades Pacific Biosciences of California (PACB) to HoldNephron analyst Jack Meehan downgraded Pacific Biosciences of California (NASDAQ: PACB) from Buy to Hold with a price target of $2.00.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Scotiabank
Reiterated
04/10/25
TD Cowen
Reiterated
04/09/25
Canaccord Genuity
Reiterated
04/09/25
Barclays
Reiterated
04/09/25
Cantor Fitzgerald
Reiterated
03/18/25
Bernstein
Reiterated
03/04/25
Piper Sandler
Reiterated
02/20/25
Goldman Sachs
Reiterated
02/18/25
Morgan Stanley
Reiterated
02/18/25
Stephens
$3.5→$2.5
Buy
83.82%
Upside
Reiterated
08/13/24
PacBio price target lowered to $2.50 from $3.50 at StephensPacBio price target lowered to $2.50 from $3.50 at Stephens
Jefferies
$4
Buy
194.12%
Upside
Initiated
06/03/24
PacBio assumed with a Buy at JefferiesPacBio assumed with a Buy at Jefferies
J.P. Morgan
―
Hold
―
Downgraded
04/21/24
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (NASDAQ: CYTH), CytomX Therapeutics (NASDAQ: CTMX) and Pacific Biosciences (NASDAQ: PACB)
Nephron
$2
Hold
47.06%
Upside
Downgraded
04/16/24
Nephron downgrades Pacific Biosciences of California (PACB) to HoldNephron analyst Jack Meehan downgraded Pacific Biosciences of California (NASDAQ: PACB) from Buy to Hold with a price target of $2.00.
Best Analysts Covering Pacific Biosciences
Which Analyst Should I Follow If I Want to Buy PACB and Sell After:
1 Month
xxx
Success Rate
5/11 ratings generated profit
Average Return
+7.85%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.45% of your transactions generating a profit, with an average return of +7.85% per trade.
3 Months
xxx
Success Rate
6/11 ratings generated profit
Average Return
-6.13%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of -6.13% per trade.
1 Year
Success Rate
4/20 ratings generated profit
Average Return
+6.72%
reiterated a buy rating 5 days ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +6.72% per trade.
2 Years
xxx
Success Rate
2/11 ratings generated profit
Average Return
-44.52%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 18.18% of your transactions generating a profit, with an average return of -44.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PACB Analyst Recommendation Trends
Rating
Nov 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
6
4
6
7
7
Buy
2
2
3
3
3
Hold
9
8
13
9
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
14
22
19
17
Each month's total comprises the sum of three months' worth of ratings.
PACB Financial Forecast
PACB Stock Forecast FAQ
What is PACB’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacific Biosciences’s 12-month average price target is $2.15.
What is PACB’s upside potential, based on the analysts’ average price target?
Pacific Biosciences has 58.09% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PACB a Buy, Sell or Hold?
Pacific Biosciences has a consensus rating of Moderate Buy which is based on 5 buy ratings, 5 hold ratings and 0 sell ratings.
What is Pacific Biosciences’s price target?
The average price target for Pacific Biosciences is $2.15. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.00 ,the lowest forecast is $1.50. The average price target represents 58.09% Increase from the current price of $1.36.
The highest analyst price target is $3.00 ,the lowest forecast is $1.50. The average price target represents 58.09% Increase from the current price of $1.36.
What do analysts say about Pacific Biosciences?
Pacific Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of PACB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.